Objective-The goal of this study was to investigate whether omega-3 polyunsaturated fatty acids (n-3 PUFA) are able to alter plasma fibrin clot properties and reduce thrombin formation in stable coronary artery disease patients undergoing percutaneous coronary intervention (PCI). Methods and Results-In an investigator-initiated, prospective, double-blind, placebo-controlled, randomized study, patients undergoing PCI who received standard pharmacotherapy were assigned to the treatment with 1 g/day n-3 PUFA (nϭ30) or placebo (nϭ24) for 1 month. Plasma fibrin clot permeability (K s ); lysis time (t 50% ); prothrombin fragment 1.2; and peak thrombin generation from automated thrombogram, 8-isoprostaglandin F 2␣ (8-iso-PGF 2␣ , an oxidative stress marker), and C-reactive protein were determined at baseline, 3 to 5 days after randomization, and 30 days after randomization. At baseline, both treatment groups did not differ significantly. A 1-month treatment with n-3 PUFA compared with placebo was associated with 15.3% higher K s , indicating larger pores in the fibrin network (Pϭ0.0005); 14.3% shorter t 50% , indicating increased susceptibility to fibrinolysis (PϽ0.0001); 33.8% lower prothrombin fragment 1.2 (Pϭ0.0013); 13.4% lower peak thrombin generation (Pϭ0.04); and 13.1% lower 8-iso-PGF 2␣ (Pϭ0.009). Treatment with n-3 PUFA had no effect on fibrinogen and C-reactive protein. Key Words: angioplasty Ⅲ fibrin Ⅲ fish oils Ⅲ thrombin Ⅲ oxidative stress A ntiplatelet and antithrombotic agents are one of the cornerstones of successful therapy of coronary artery disease (CAD). Despite antiplatelet treatment with acetylsalicylic acid and clopidogrel, some patients undergoing percutaneous coronary intervention (PCI) and after acute coronary syndromes (ACS) still experience thrombotic events, including stent thrombosis and recurrent myocardial infarction. 1,2 Platelet activation is closely associated with blood coagulation activation, resulting in a surge of thrombin generation that leads ultimately to fibrin clot formation. 2 As thrombin is also a potent platelet activator, inhibition of thrombin generation, thrombin activity, or both might improve treatment outcomes of CAD patients.
A ntiplatelet and antithrombotic agents are one of the cornerstones of successful therapy of coronary artery disease (CAD). Despite antiplatelet treatment with acetylsalicylic acid and clopidogrel, some patients undergoing percutaneous coronary intervention (PCI) and after acute coronary syndromes (ACS) still experience thrombotic events, including stent thrombosis and recurrent myocardial infarction. 1, 2 Platelet activation is closely associated with blood coagulation activation, resulting in a surge of thrombin generation that leads ultimately to fibrin clot formation. 2 As thrombin is also a potent platelet activator, inhibition of thrombin generation, thrombin activity, or both might improve treatment outcomes of CAD patients.
A relationship between the structure/function of a fibrin clot and the presence of cardiovascular disease was first demonstrated in patients with advanced CAD in 1992. 3 Fibrin clots composed of dense fiber networks, which display lower clot permeability (by approximately 30% compared with control subjects), have been found in men with myocardial infarction and aged less than 45 years. 3 Collet et al reported that fibrin clots obtained from 33 young survivors of myocardial infarction had increased stiffness and number of shorter fibers that were associated with slower fibrinolysis compared with healthy controls. 4 It has been shown that intracoronary thrombi removed from coronary arteries are highly organized and rich in fibrin when myocardial revas-cularization is performed more than 6 hours after the onset of chest pain. 5, 6 We have demonstrated that compared with stable CAD, ACS are associated with the formation of significantly less permeable and lysable fibrin clots obtained from plasma of peripheral venous blood drawn within the first 12 hours from chest pain onset. 7 Of note, clot permeability and fibrinolysis in ACS patients were determined by the degree of oxidative stress and stimulation of inflammation. 7 Such abnormalities in fibrin clot structure and function predisposing to thrombotic events were also demonstrated in patients with no-reflow phenomenon during PCI and stent thrombosis. 8, 9 A number of beneficial effects of n-3 polyunsaturated fatty acids (n-3 PUFA) in the management of cardiovascular risk have been reported in the literature. 10 It has also been demonstrated that n-3 PUFA may affect blood coagulation via several mechanisms. In an animal model of apolipoprotein E2 knock-in hyperlipidemic mice, the administration of fish oil resulted in the reduction of coagulation factor (F) V, prothrombin, FVII and FX. 11 It has been shown that in apparently healthy subjects, n-3 PUFA can increase or decrease plasma fibrinogen and clotting factors, in particular FVII activity, FVIII, and von Willebrand factor concentrations. 12, 13 Evidence also indicates that fish oil supplementation may reduce thrombin generation 11, 14 and enhance fibrinolysis. 15 Conversely, other studies failed to demonstrate significant changes in circulating markers of thrombosis following administration of n-3 PUFA. 16 The antiplatelet effect of n-3 PUFA has been explored with inconsistent findings. 13 Recently, we have demonstrated that the addition of n-3 PUFA to the combination of aspirin and clopidogrel significantly potentiates platelet response to clopidogrel after PCI. 17 So far, there have been no studies evaluating the effects of n-3 PUFA on fibrin clot properties in combination with thrombin generation, inflammation, and oxidative stress in CAD patients after PCI treated with aspirin and clopidogrel. Both aspirin and clopidogrel might affect coagulation beyond strictly antiplatelet actions. In some models, aspirin can reduce thrombin generation 2, 18 and increase clot permeability and susceptibility to lysis. 2, 19 It has also been suggested that clopidogrel alters fibrin-platelet clot formation determined by thromboelastography 2 ; however, this agent does not affect thrombin formation. 20, 21 As increased consumption of oily fish or supplementation with ethyl esters of n-3 PUFA has already been recommended following acute myocardial infarction, their effect on blood coagulation merits further investigation. 1 The objective of the current study was to evaluate the effects of n-3 PUFA administered on top of aspirin and clopidogrel on plasma fibrin clot properties and thrombin generation and its relationship to oxidative stress and inflammation in stable CAD patients undergoing PCI.
Methods
We studied 54 patients aged 30 to 80 with stable CAD after successful PCI with stent implantation enrolled in the OMEGA-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy (OMEGA-PCI) Study, an investigator-initiated, prospective, single-center, double-blind, placebo-controlled, randomized study evaluating the effects of n-3 PUFA on platelet responsiveness to dual antiplatelet therapy with aspirin and clopidogrel. 17 Exclusion criteria were as follows: ACS, a history of bleeding, oral anticoagulant therapy, thienopyridine use before enrolment, platelet count Ͻ100,000/L, serum creatinine Ͼ177 mol/L (2 mg/dL), or liver injury (alanine transaminase Ͼ1.5 times above the upper limit of the reference range). Patients were advised against the use of nonsteroidal antiinflammatory drugs.
The complete study design is presented elsewhere. 17 Briefly, eligible patients on chronic acetylsalicylic acid therapy were randomly assigned before PCI to receive clopidogrel (loading dose, 600 mg; afterward, 75 mg once daily) and 1000 mg once daily of either n-3 PUFA or placebo for 4 weeks. n-3 PUFA were administered in a preparation containing ethyl esters of 460 mg of eicosapentaenoic acid and 380 mg of docosahexaenoic acid (Omacor, Pronova Biocare/Solvay Pharma Poland). Patients were also asked to comply with a diet recommended by European Society of Cardiology that encouraged increased consumption of oily fish. 1 Compliance with medication usage was assessed from the number of tablets returned at each visit in both groups.
The primary objective of the main study was to determine whether n-3 PUFA were able to modify platelet responsiveness to dual antiplatelet therapy in stable CAD patients undergoing PCI, and the sample size was calculated accordingly. 17 The prespecified analysis that is reported here was designed to assess the effect of n-3 PUFA on fibrin clot permeability, thrombin generation, inflammation, and oxidative stress. Because blood samples were collected during the OMEGA-PCI Study, patients receiving placebo were included in the final analysis if samples were available.
The assessment during the study was performed at 3 time points: before clopidogrel and study medication loading, at discharge from the hospital 3 to 5 days after PCI, and 1 month after randomization. The occurrence of both ischemic and bleeding events was recorded.
The study was compliant with the Good Clinical Practice International Conference on Harmonisation rules and was approved by the Ethics Committee of the Jagiellonian University. Each patient provided written informed consent before entering the study.
Laboratory Investigations
Fasting blood samples were drawn between 8:00 and 10:00 AM from an antecubital vein with minimal stasis. Routine blood tests, including lipid profile, blood cell count, glucose, and serum creatinine, were carried out by automated laboratory techniques. Plasma samples (9:1 of 3.2% trisodium citrate) for the fibrin clot analysis were centrifuged (20 minutes, 2500g) within 30 minutes of collection, immediately frozen, and stored in aliquots at Ϫ80°C. For the assessments of platelet aggregation, the citrated blood samples were processed within 2 hours after sampling. Fibrinogen and highsensitivity C-reactive protein were measured by latex nephelometry (Dade Behring, Marburg, Germany). Immunoenzymatic assays were used to determine 8-isoprostaglandin F 2␣ (8-iso-PGF 2␣ ), a stable marker of oxidative stress (Cayman Chemicals, Ann Arbor, MI) and prothrombin fragment 1.2 (F1.2) (Siemens, Marburg, Germany). Plasma prothrombin (FII) was measured by 1-stage clotting assays using factor-deficient plasma (Dade Behring, Liederbach, Germany). FXIII levels were measured with the Berichrom FXIII test (Siemens). Investigators blinded to the sample origin performed all laboratory investigations. The interassay and intraassay coefficients of variation for all the ELISAs were Ͻ8% (nϭ20).
Fibrin Clot Permeability
Fibrin clot permeation properties were determined as previously described. 7, 18 Briefly, 20 mmol/L calcium chloride and 1 U/mL human thrombin (Sigma-Aldrich, St Louis, MO) were added to 120 L of citrated plasma. After incubation in a wet chamber for 120 minutes, tubes containing the clots were connected to a reservoir of a buffer (10 mmol/L: 0.05 mol/L Tris-HCl; 100 mmol/L: 0.15 mol/L NaCl, pH 7.5), and its volume flowing through the gels was measured within 60 minutes. A permeation coefficient (K s ), which indicates the size of fibrin clot pores, was calculated from the following equation: K s ϭQϫLϫ/tϫAϫ⌬p, where Q is the flow rate in time t, L is the length of a fibrin gel (13 mm), is the viscosity
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Plasma Clot Lysis Assays
Plasmin-mediated fibrinolysis in the presence of recombinant tissue plasminogen activator (Boehringer Ingelheim, Ingelheim, Germany) was evaluated as previously described. 7, 18 Briefly, 100 L of citrated plasma was diluted with 100 L of a buffer (0.05 mol/L Tris-HCl, 0.15 mol/L NaCl, pH 7.4), containing 20 mmol/L calcium chloride, 1 U/mL human thrombin (Sigma-Aldrich), and 1 mol/L recombinant tissue plasminogen activator. The assembly kinetics was monitored by spectrophotometry at 405 nm in duplicate aliquots. Lysis time was defined as the time required for a 50% decrease in fibrin clot absorbance (t 50% ) and was chosen as a marker of the clot susceptibility to fibrinolysis. The interassay and intraassay coefficients of variation were below Ͻ8% (nϭ22).
Thrombin Generation Potential
To assess plasma thrombogenic potential, the thrombogram was analyzed using the CAT (Thrombinoscope BV, Maastricht, the Netherlands) according to the manufacturer's instructions in the 96-well plate fluorometer (Ascent Reader, Thermolabsystems OY, Helsinki, Finland) equipped with the 390/460 filter set at a temperature of 37°C. Eighty microliters of platelet-poor plasma was diluted with 20 L of the reagent containing 5 pmol/L recombinant tissue factor, 4 micromolar phosphatidylserine/phosphatidylcholine/phosphatidylethanolamine vesicles, and 20 L of FluCa solution (Hepes, pH 7.35, 100 nmol/L CaCl 2 , 60 mg/mL bovine albumin, and 2.5 mmol/L Z-Gly-Gly-Arg-amido metyl coumarin). Each plasma sample was analyzed in duplicate, and the intraassay variability was 6%. For analysis, the maximum concentration of thrombin generated (C max ) was used.
Platelet Aggregation
Platelet aggregation was assessed as previously described. 17 Briefly, P2Y 12 reactivity index was calculated by assessment of the phosphorylated status of vasodilator-stimulated phosphoprotein according to standard protocols and a standardized assay (Platelet VASP, Biocytex Inc, Asnieres, France) with quantitative flow cytometry (FACSCalibur system, BD Bioscience).
Light transmittance aggregometry was performed with a 2-channel Chronolog Aggregometer (Chrono-Log 490, Chrono-Log). Platelets were stimulated with 0.5 mmol/L arachidonic acid. Platelet aggregation was expressed as maximal percentage change in light transmittance from baseline using platelet-poor plasma as a reference.
Statistical Analysis
Statistical analyses were performed with Statistica 6.0 PL software package. Continuous variables were expressed as meanϮSD and categorical variables as number (percentage). Continuous variables were first checked for normal distribution by the Shapiro-Wilk statistic and the Bera-Jarque test and then compared by the MannWhitney U test. ANOVA for repeated measures, with both contrast analysis for intergroup difference at each time point and post hoc analysis with Bonferroni correction for intragroup changes between different time points, was used for comparison of fibrin clot properties, thrombin concentration and generation, oxidative stress parameters, and platelet reactivity. The 2 test, with or without the Yates continuity correction, was used to evaluate the differences in categorical variables between the respective study groups when appropriate. The Pearson or Spearman rank correlation coefficient was calculated to test the association between 2 variables with a normal or nonnormal distribution, respectively. All clinical, laboratory, and angiographic variables that showed the association with K s in univariate model (PՅ0.2) and did not show substantial correlations (rϾ0.5) with another independent variable were then included in the multiple linear regression analysis to determine independent predictor of clot permeability after 1 month of treatment. All statistic tests were 2-sided. A probability value Ͻ0.05 was considered statistically significant.
The study was powered to have an 90% chance of detecting a 15% difference in the plasma clot properties between the compared groups using a probability value of 0.05, based on the values of fibrin features in the published articles. 8, 9 To demonstrate such a difference or greater, at least 23 patients were required in each group.
Results
Fifty-four patients (41 male and 13 female; aged 62.8Ϯ9.5 years) with stable CAD undergoing successful PCI with stent implantation were analyzed. Baseline demographics, clinical and procedural characteristics, and concomitant medications of the randomized subjects are shown in Table  1 and Supplemental Table I , available online at http://atvb. ahajournals.org. There were no significant differences among most baseline variables. Creatinine was slightly lower in the n-3 PUFA group, although a history of chronic kidney disease was less frequent in that group (Table 1) . No intergroup difference was observed in plasma fibrinogen at baseline and throughout the study (Table 2) . During the study period, there were no changes in concomitant medications.
Fibrin Clot Properties
Baseline K s and t 50% values were similar in both groups. Compared with placebo, K s gradually increased during 1 month of treatment with n-3 PUFA (PϽ0.0001). After 1 month of treatment with n-3 PUFA, the permeability coefficient was 15.3% higher compared with placebo (Pϭ0.0005), indicating larger pores in the fibrin network (Figure) . Compared with placebo, clot lysis time gradually decreased during 1 month of treatment with n-3 PUFA (PϽ0.0001). After 1 month of treatment with n-3 PUFA, t 50% was shorter by 14.3% compared with placebo (PϽ0.0001), indicating increased clot susceptibility to fibrinolysis induced by n-3 PUFA (Figure) . There were no significant changes in either K s (Pϭ0.76) or t 50% (Pϭ0.62) values during the study in patients who received placebo.
As expected, K s was inversely correlated with t 50% at baseline (rϭϪ0.89, PϽ0.001) as well as in n-3 PUFA and the placebo groups after 3 to 5 days (rϭϪ0.94 and Ϫ0.91, respectively, PϽ0.001) and after 1 month (rϭϪ0.94 and Ϫ0.89, PϽ0.001). K s was also inversely correlated with fibrinogen at baseline (rϭϪ0.74, PϽ0.0001) and in both groups after 1 month (rϭϪ0.75 and Ϫ0.66, PϽ0.01). t 50% was positively correlated with fibrinogen at baseline (rϭ0.69, PϽ0.0001) and in both groups after 1 month (rϭϪ0.68 and Ϫ0.63, PϽ0.05). There was no correlation between fibrin clot properties and C-reactive protein. All correlations between clinical, laboratory, and fibrin clot variables are shown in Supplemental Table II .
Thrombin Generation
Compared with placebo, 1 month of treatment with n-3 PUFA on top of dual antiplatelet therapy resulted in a gradual reduction in plasma F1.2 concentration (Pϭ0.0005). After a 1-month treatment, patients who received n-3 PUFA had lower F1.2 by 33.8% (Pϭ0.0013) and C max by 13.4% (Pϭ0.04), indicating decreased thrombin generation (Figure) . In the placebo group, there were no significant changes in F1.2 and C max during the study (Figure) .
In patients who received n-3 PUFA, but not in the placebo group, we found inverse correlations between F1.2 and both clot permeability and t 50% after 3 to 5 days (rϭϪ0.81, PϽ0.001, and rϭ0.71, Pϭ0.002 respectively) and after 1 month (rϭϪ0.52, Pϭ0.031, and rϭ0.62, Pϭ0.008). Similar significant correlations were also found between C max and fibrin clot properties (Supplemental Table II ). There were also significant positive correlations between F1.2 and C max at all time points in both groups (rϭ0.72 to 0.89, PϽ0.0001 for all). We observed neither significant changes in the plasma levels of coagulation factors II and XIII throughout the study in both groups nor significant correlations between those factors and fibrin clot properties (Table 2 and Supplemental  Table II) .
Oxidative Stress
Compared with placebo, 1 month of treatment with n-3 PUFA was associated with significant reduction in plasma 8-iso-PGF 2␣ concentration (Pϭ0.003). During treatment period, 8-iso-PGF 2␣ decreased by 27.4% in patients receiving n-3 PUFA (PϽ0.0001) and by 11.5% in the placebo group (Pϭ0.43). After 1 month, plasma 8-iso-PGF 2␣ was lower by 13.1% in patients who received n-3 PUFA compared with those on placebo (Pϭ0.009) ( Table 2) .
Of note, there was a negative correlation between 8-iso-PGF 2␣ and clot permeability both at baseline (rϭϪ0.66, PϽ0.001) and after 1 month of treatment in the placebo and n-3 groups (rϭϪ0.55 and Ϫ0.65, respectively, PϽ0.05). There was also a positive correlation between 8-iso-PGF 2␣ and t 50% at baseline (rϭ0.64, PϽ0.001) and after 1 month of treatment in both groups (rϭ0.47 and 0.52, PϽ0.05) (Supplemental Table II) .
Platelet Reactivity
Similar to what we have shown previously, 17 the P2Y 12 reactivity index was lower by 17.1% after 1 month of treatment with n-3 PUFA compared with placebo when used in addition to dual antiplatelet therapy (Pϭ0.03) ( Table 2) . Platelet aggregation after arachidonic acid stimulation was low and did not change significantly throughout the study (Pϭ0.11).
There were no correlations between plasma fibrin clot permeability, lysis time, F1.2, C max , and 8-iso-PGF 2␣ with on-treatment platelet reactivity assessed by platelet function tests during the entire study period in both groups (Supplemental Table II) .
Adverse Events and Independent Predictors of Clot Permeability
The adverse events that occurred during the study were rated as mild, and their frequency did not differ significantly between groups. The number of patients reporting minor bruising was similar in both groups (5 patients in the n-3 PUFA and 3 patients in the placebo group) and did not require medical intervention. There were no major cardiac adverse events during 1-month follow-up in either group.
As the OMEGA-PCI Clot was a subanalysis of a randomized study, a multiple linear regression model was applied to determine independent predictors of fibrin clot properties. After 1 month of treatment, fibrinogen, treatment assignment, and 8-iso-PGF 2␣ were independently associated with clot permeability (PϽ0.0001, R 2 ϭ0.66; Table 3 ).
Discussion
The current study is the first to demonstrate that n-3 PUFA added to standard dual antiplatelet therapy after PCI favorably alter plasma clot properties compared with placebo. In CAD patients who received n-3 PUFA along with clopidogrel and aspirin, fibrin clots formed from plasma had a less compact structure that was less resistant to lysis. We also found that fibrin clot variables correlated with thrombin generation and oxidative stress markers. Treatment with n-3 PUFA did not reduce fibrinogen level, which is recognized to be a key modulator of fibrin clot structure. 22, 23 Therefore, alterations in fibrin clot characteristics in this study cannot be explained by reduction in fibrinogen. Of note, n-3 PUFA intake in our study reduced thrombin formation, reflected by both the thrombin present in plasma (F1.2) and the amount of thrombin that can be generated in vivo (C max ), and oxidative stress determined in circulating blood. It had been demonstrated that thrombin generation and the degree of oxidative stress, reflected by 8-isoprostanes in circulating blood, affect fibrin clot properties. 7, 23, 24 We have shown significant associations of clot permeability and clot lysis with F1.2, C max , and 8-iso-PGF 2␣ , clearly indicating that improved clot characteristics could result at least in part from suppressed thrombin formation and free radical generation. We also demonstrated that n-3 PUFA did not lower prothrombin or FXIII levels in PCI patients; therefore, these factors cannot account for the observed alterations in clot phenotype. n-3 PUFA are highly unsaturated and therefore prone to oxidation. It was previously demonstrated that supplementation with n-3 PUFA decreased plasma level of 8-iso-PGF 2␣ in healthy humans and in treated hypertensive type 2 diabetic subjects. 25, 26 On the contrary, there have been reports that consumption of fish oil in certain circumstances might increase lipid peroxidation and oxidative damage. 27 To our knowledge, this is the first report to demonstrate that in patients with CAD receiving modern pharmacotherapy, n-3 PUFA decrease 8-isoprostane formation during nonenzymatic arachidonic acid peroxidation in vivo which suggests that these agents may suppress oxidative stress-mediated adverse effects in CAD patients, including dense fibrin clot formation. 28 Oxidative stress leads to protein modification, although data yielded inconsistent findings. 29 Oxidized fibrinogen may promote fibrinogen conversion to fibrin, enhance platelet aggregation, and less efficiently support plasminogen activation. 29 Blood coagulation and platelet activation are closely linked and interrelated. As thrombin is a potent platelet agonist, decreased thrombin generation induced by n-3 PUFA is likely to contribute to improved platelet response to clopidogrel, as previously demonstrated. 17 On the other hand, fibrin structure is influenced by platelets, including platelet-derived ␤-thromboglobulin and platelet factor-4, as well as a negatively charged polyphosphate. 7, 30, 31 All these factors have been shown to result in the formation of denser fibrin clots, which are characterized by increased resistance to lysis. It remains unclear whether decreased platelet activity reflected by platelet aggregation may contribute to alterations in fibrin clot properties evaluated ex vivo in a citrated plasma-based system. Importantly, altered plasma clot properties in patients who received n-3 PUFA were apparent despite administration of drugs that can increase clot permeability and promote lysis. 23, 32 Ajjan et al demonstrated that aspirin favorably alters fibrin clot structure and function. 19 However, in CAD patients, beneficial effects of low-dose aspirin in fibrin formation and lysis could be abolished by several prothrombotic mechanisms. 33 Moreover, several studies indicate that fibrin clot properties can be favorably altered by statins. [32] [33] [34] Given the fact that almost all the patients studied were taking both aspirin and a statin, we could not assess the effects of these drugs. However, it might be hypothesized that the impact of n-3 PUFA on fibrin clots is potent enough to be detectable despite similar beneficial effects produced by aspirin and statins.
The effect of clopidogrel on thrombin generation is a subject of controversy. It has been shown that there is neither a clopidogrel-induced reduction of thrombin formation following vascular injury 21 nor a delayed thrombin-induced platelet-fibrin clot formation. 2 We have demonstrated that clopidogrel added to aspirin in the placebo group does not influence thrombin generation, which is consistent with previous reports. 20, 21 Our original observation is the lack of changes in plasma fibrin clot properties following clopidogrel administration. Given the effect of clopidogrel on clots obtained from whole blood, 2 our observations confirmed that blood cells and platelets are important contributors to thrombus characteristics. 35 The study has several limitations. First, the sample size is limited. However, although the study was randomized, both groups were well matched and represent typical stable angina patients undergoing PCI. Second, scanning electron microscopy of fibrin clots has not been performed. We believe that functional plasma-based assays provide more valuable insights into a role of fibrin clots in atherothrombosis. Third, we cannot extrapolate our current findings to high-risk patients exhibiting increased thrombin formation, for example, those with ACS, because they were excluded from this study. Fourth, the effect of n-3 PUFA alone in healthy individuals or cardiovascular patients free of aspirin and clopidogrel has not been explored yet. Finally, we did not evaluate clinical end points to finally establish whether the effect of n-3 PUFA on fibrin structure and thrombin generation improved clinical outcomes during follow-up. This issue requires a different study design, and it was beyond scope of this investigation.
In conclusion, our results demonstrated improved clot properties and decreased thrombin formation after treatment with n-3 PUFA in CAD patients, indicating novel antithrombotic effects produced by these agents. These effects may contribute to a decreased risk of thrombotic events after PCI following n-3 PUFA administration. A larger study is needed to assess clinical benefits potentially related to these novel antithrombotic effects of n-3 PUFA.
